Two faces of the estrogen metabolite 2-methoxyestradiol in vitro and in vivo

Lee,Ji‑Sun; Kim,Yu‑Kyung; Yang,Hyun; Kang,Hee  Young; Ahn,Changhwan; Jeung,Eui‑Bae

doi:10.3892/mmr.2015.4073

Two faces of the estrogen metabolite 2-methoxyestradiol in vitro and in vivo

Authors:
- Ji‑Sun Lee
- Yu‑Kyung Kim
- Hyun Yang
- Hee Young Kang
- Changhwan Ahn
- Eui‑Bae Jeung
View Affiliations

Affiliations: Laboratory of Veterinary Biochemistry and Molecular Biology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 362‑763, Republic of Korea
Published online on: July 13, 2015 https://doi.org/10.3892/mmr.2015.4073
Pages: 5375-5382

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

2-Methoxyestradiol (2-ME), an endogenous metabolite of 17β-estradiol (E2), interacts with estrogen receptors (ERs) and microtubules, however, 2-ME has a low affinity for ERs. Furthermore, 2‑ME has been identified as a potential novel antitumor agent, combining its anti‑proliferative effects on a variety of tumor cell types with its anti‑angiogenic action. Therefore, 2‑ME is of interest due to its potential anticancer therapeutic effects. In the current study, the estrogenic effect of 2‑ME on CaBP‑9k, ERα, and progesterone receptor (PR) mRNA levels in the absence and presence of E2 and progesterone (P4) in in vivo and in vitro models was examined. In GH3 cells, the mRNA level of CaBP‑9k was induced in the E2 treatment group (concentration, 10‑9 M), and the expression of CaBP‑9k was also upregulated in the 2‑ME‑treated group (concentration, 10‑7 M). Uterine lactoferrin (Ltf) mRNA expression was also increased in the 2‑ME group [dose, 40 mg/kg body weight (BW)], which was comparable to the response with E2 (dose, 40 µg/kg BW) observed in mice. As inhibitors of ER and PR activity, ICI 182,780 and mifepristone (RU486) were observed to reverse the E2 or 2‑ME mediated increase of CaBP‑9k and Ltf mRNA expression. In addition, it was found that 2‑ME significantly decreased the levels of ERα and increased PR transcripts. Consistent with the in vitro results, the mRNA levels revealed decreased ERα and increased PR in in vivo treatment of E2 and 2‑ME. These findings demonstrate that the expression of estrogenic markers, CaBP‑9k and Ltf, is regulated by 2‑ME in in vitro and in vivo models, therefore, estrogenic activities of 2-ME may be increased in females during the estrous cycle via the ER and/or PR-mediated signaling pathway.

View Figures

View References

1	Wang SH, Myc A, Koenig RJ, Bretz JD, Arscott PL and Baker JR: 2-Methoxyestradiol, an endogenous estrogen metabolite, induces thyroid cell apoptosis. Mol Cell Endocrinol. 165:163–172. 2000. View Article : Google Scholar : PubMed/NCBI
2	Männistö PT and Kaakkola S: Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 51:593–628. 1999.PubMed/NCBI
3	Zhang Y, Gaikwad NW, Olson K, Zahid M, Cavalieri EL and Rogan EG: Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 56:887–894. 2007. View Article : Google Scholar : PubMed/NCBI
4	Spady TJ, McComb RD and Shull JD: Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland. Endocrine. 11:217–233. 1999. View Article : Google Scholar
5	Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM and Green SJ: 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 19:173–179. 2000. View Article : Google Scholar
6	Hamel E, Lin CM, Flynn E and D'Amato RJ: Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry. 35:1304–1310. 1996. View Article : Google Scholar : PubMed/NCBI
7	Banerjeei SK, Zoubine MN, Sarkar DK, Weston AP, Shah JH and Campbell DR: 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: Possible role of vascular endothelial growth factor. Anticancer Res. 20:2641–2645. 2000.PubMed/NCBI
8	D'Amato RJ, Lin CM, Flynn E, Folkman J and Hamel E: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA. 91:3964–3968. 1994. View Article : Google Scholar : PubMed/NCBI
9	Attalla H, Westberg JA, Andersson LC, Adlercreutz H and Mäkelä TP: 2-Methoxyestradiol-induced phosphorylation of Bcl-2: Uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun. 247:616–619. 1998. View Article : Google Scholar : PubMed/NCBI
10	Chang I, Majid S, Saini S, Zaman MS, Yamamura S, Chiyomaru T, Shahryari V, Fukuhara S, Deng G, Dahiya R, et al: Hrk mediates 2-methoxyestradiol-induced mitochondrial apoptotic signaling in prostate cancer cells. Mol Cancer Ther. 12:1049–1059. 2013. View Article : Google Scholar : PubMed/NCBI
11	Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, et al: Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst. 105:1496–1503. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yue W, Yager JD, Wang JP, Jupe ER and Santen RJ: Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids. 78:161–170. 2013. View Article : Google Scholar
13	Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, et al: Beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res. 65:9406–9414. 2005. View Article : Google Scholar : PubMed/NCBI
14	Zhu BT and Conney AH: Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 58:2269–2277. 1998.PubMed/NCBI
15	Brueggemeier RW and Singh U: Inhibition of rat liver microsomal estrogen 2-hydroxylase by 2-methoxyestrogens. J Steroid Biochem. 33:589–593. 1989. View Article : Google Scholar : PubMed/NCBI
16	Tinnanooru P, Dang VH, Nguyen TH, Lee GS, Choi KC and Jeung EB: Estrogen regulates the localization and expression of calbindin-D9k in the pituitary gland of immature male rats via the ERalpha-pathway. Mol Cell Endocrinol. 285:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
17	Lee GS, Choi KC, Park SM, An BS, Cho MC and Jeung EB: Expression of human Calbindin-D (9k) correlated with age, vitamin D receptor and blood calcium level in the gastrointestinal tissues. Clin Biochem. 36:255–261. 2003. View Article : Google Scholar : PubMed/NCBI
18	Dang VH, Nguyen TH, Choi KC and Jeung EB: A calcium-binding protein, calbindin-D9k, is regulated through an estrogen-receptor mediated mechanism following xenoestrogen exposure in the GH3 cell line. Toxicol Sci. 98:408–415. 2007. View Article : Google Scholar : PubMed/NCBI
19	Hong EJ, Park SH, Choi KC, Leung PC and Jeung EB: Identification of estrogen-regulated genes by microarray analysis of the uterus of immature rats exposed to endocrine disrupting chemicals. Reprod Biol Endocrinol. 4:492006. View Article : Google Scholar : PubMed/NCBI
20	Walmer DK, Wrona MA, Hughes CL and Nelson KG: Lactoferrin expression in the mouse reproductive tract during the natural estrous cycle: Correlation with circulating estradiol and progesterone. Endocrinology. 131:1458–1466. 1992.PubMed/NCBI
21	Newbold RR, Teng CT, Beckman WC Jr, Jefferson WN, Hanson RB, Miller JV and McLachlan JA: Fluctuations of lactoferrin protein and messenger ribonucleic acid in the reproductive tract of the mouse during the estrous cycle. Biol Reprod. 47:903–915. 1992. View Article : Google Scholar : PubMed/NCBI
22	Fujimoto N, Jinno N and Kitamura S: Activation of estrogen response element dependent transcription by thyroid hormone with increase in estrogen receptor levels in a rat pituitary cell line, GH3. J Endocrinol. 181:77–83. 2004. View Article : Google Scholar : PubMed/NCBI
23	Banerjee SN, Sengupta K, Banerjee S, Saxena NK and Banerjee SK: 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: A possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia. 5:417–426. 2003. View Article : Google Scholar : PubMed/NCBI
24	Yang H, Nguyen TT, An BS, Choi KC and Jeung EB: Synergistic effects of parabens on the induction of calbindin-D (9k) gene expression act via a progesterone receptor-mediated pathway in GH3 cells. Hum Exp Toxicol. 31:134–144. 2012. View Article : Google Scholar
25	Vo TT, An BS, Yang H, Jung EM, Hwang I and Jeung EB: Calbindin-D9k as a sensitive molecular biomarker for evaluating the synergistic impact of estrogenic chemicals on GH3 rat pituitary cells. Int J Mol Med. 30:1233–1240. 2012.PubMed/NCBI
26	Jung EM, An BS, Choi KC and Jeung EB: Potential estrogenic activity of triclosan in the uterus of immature rats and rat pituitary GH3 cells. Toxicol Lett. 208:142–148. 2012. View Article : Google Scholar
27	Vo TT, Jung EM, Choi KC, Yu FH and Jeung EB: Estrogen receptor α is involved in the induction of Calbindin-D (9k) and progesterone receptor by parabens in GH3 cells: A biomarker gene for screening xenoestrogens. Steroids. 76:675–681. 2011. View Article : Google Scholar : PubMed/NCBI
28	Ahn HJ, Yang H, An BS, Choi KC and Jeung EB: Expression and regulation of Enpp2 in rat uterus during the estrous cycle. J Vet Sci. 12:379–385. 2011. View Article : Google Scholar : PubMed/NCBI
29	Wang Y, Tu Y, Han F, Xu Z and Wang J: Developmental gene expression of lactoferrin and effect of dietary iron on gene regulation of lactoferrin in mouse mammary gland. J Dairy Sci. 88:2065–2071. 2005. View Article : Google Scholar : PubMed/NCBI
30	Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP and Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 368:237–239. 1994. View Article : Google Scholar : PubMed/NCBI
31	Krisinger J, Setoyama T and Leung PC: Expression of calbindin-D9k in the early pregnant rat uterus: Effects of RU 486 and correlation to estrogen receptor mRNA. Mol Cell Endocrinol. 102:15–22. 1994. View Article : Google Scholar : PubMed/NCBI
32	Krisinger J, Dann JL, Currie WD, Jeung EB and Leung PC: Calbindin-D9k mRNA is tightly regulated during the estrous cycle in the rat uterus. Mol Cell Endocrinol. 86:119–123. 1992. View Article : Google Scholar : PubMed/NCBI
33	Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ and Turner RT: Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology. 144:785–792. 2003. View Article : Google Scholar : PubMed/NCBI
34	Williams K, McKinnell C, Saunders PT, Walker M, Fisher JS, Turner KJ, Atanassova N and Sharpe M: Neonatal exposure to potent and environmental oestrogens and abnormalities of the male reproductive system in the rat: Evidence for importance of the androgenoestrogen balance and assessment of the relevance to man. Hum Reprod Update. 7:236–247. 2001. View Article : Google Scholar : PubMed/NCBI
35	Swedenborg E, Pongratz I and Gustafsson JA: Endocrine disruptors targeting ERbeta function. Int J Androl. 33:288–297. 2010. View Article : Google Scholar : PubMed/NCBI
36	Keightley MC: Steroid receptor isoforms: Exception or rule? Mol Cell Endocrinol. 137:1–5. 1998. View Article : Google Scholar : PubMed/NCBI
37	Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al: The nuclear receptor superfamily: The second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
38	Akbas GE, Fei X and Taylor HS: Regulation of HOXA10 expression by phytoestrogens. Am J Physiol Endocrinol Metab. 292:E435–E442. 2007. View Article : Google Scholar
39	Kim YR, Jung EM, Choi KC and Jeung EB: Synergistic effects of octylphenol and isobutyl paraben on the expression of calbindin-D (9)k in GH3 rat pituitary cells. Int J Mol Med. 29:294–302. 2012.
40	Mooberry SL: New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol. 15:425–430. 2003. View Article : Google Scholar : PubMed/NCBI
41	Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI
42	Liu ZJ and Zhu BT: Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol. 88:265–275. 2004. View Article : Google Scholar : PubMed/NCBI
43	Turner RT and Evans GL: 2-Methoxyestradiol inhibits longitudinal bone growth in normal female rats. Calcif Tissue Int. 66:465–469. 2000. View Article : Google Scholar : PubMed/NCBI
44	Takanashi K, Honma T, Kashiwagi T, Honjo H and Yoshizawa I: Detection and measurement of urinary 2-hydroxyestradiol 17-sulfate, a potential placental antioxidant during pregnancy. Clin Chem. 46:373–378. 2000.PubMed/NCBI
45	Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BV and Reed MJ: Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer. 90:932–937. 2004. View Article : Google Scholar : PubMed/NCBI